Search tips
Search criteria 


Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. 2010 May; 54(5): 2143–2151.
Published online 2010 March 8. doi:  10.1128/AAC.01391-09
PMCID: PMC2863653

Systematic Approach to Optimizing Specifically Targeted Antimicrobial Peptides against Streptococcus mutans[down-pointing small open triangle]


Previously we reported a novel strategy of “targeted killing” through the design of narrow-spectrum molecules known as specifically targeted antimicrobial peptides (STAMPs) (R. Eckert et al., Antimicrob. Agents Chemother. 50:3651-3657, 2006; R. Eckert et al., Antimicrob. Agents Chemother. 50:1480-1488, 2006). Construction of these molecules requires the identification and the subsequent utilization of two conjoined yet functionally independent peptide components: the targeting and killing regions. In this study, we sought to design and synthesize a large number of STAMPs targeting Streptococcus mutans, the primary etiologic agent of human dental caries, in order to identify candidate peptides with increased killing speed and selectivity compared with their unmodified precursor antimicrobial peptides (AMPs). We hypothesized that a combinatorial approach, utilizing a set number of AMP, targeting, and linker regions, would be an effective method for the identification of STAMPs with the desired level of activity. STAMPs composed of the Sm6 S. mutans binding peptide and the PL-135 AMP displayed selectivity at MICs after incubation for 18 to 24 h. A STAMP where PL-135 was replaced by the B-33 killing domain exhibited both selectivity and rapid killing within 1 min of exposure and displayed activity against multispecies biofilms grown in the presence of saliva. These results suggest that potent and selective STAMP molecules can be designed and improved via a tunable “building-block” approach.

Pathogenic microorganisms have been a continuous source of human suffering and mortality throughout the course of human history and have spurred the clinical development of novel therapeutics. Even today, the overall burden of infectious disease remains high, constituting a leading (and rising) cause of death worldwide (16, 18). The conventional medical response to bacterial infections, administration of small-molecule antibiotics, has become less effective against emerging pathogens due to the evolution of drug resistance stemming in part from the misuse of antibiotics (13). Additionally, antibiotics and oral antiseptics currently in use to treat mucosal infections eliminate pathogens and bystander bacteria alike, an outcome that can be associated with negative clinical consequences (15, 17). Therefore, there is an unmet medical need to develop novel, narrow-spectrum therapeutics capable of maintaining the protective benefits of the normal microflora during treatment.

Our strategy for creating novel, selective antibacterial agents is based on the addition of a targeting peptide to an existing broad-spectrum antimicrobial peptide (AMP), thereby generating a specifically targeted antimicrobial peptide (STAMP) selective for a particular bacterial species or strain. A completed STAMP consists of conjoined but functionally independent targeting and killing regions, separated by a small flexible linker, all within a linear peptide sequence. The STAMP targeting region drives enhancement of antimicrobial activity by increasing binding to the surface of a targeted pathogen, utilizing specific determinants such as overall membrane hydrophobicity, charge, and/or pheromone receptors, which in turn leads to increased selective accumulation of the killing moiety (6, 7).

As both the killing and targeting regions of the STAMP are linear peptides, we approached the design process using a tunable combinatorial methodology where, for example, the targeting peptide component is held constant, while a number of killing peptides are conjoined utilizing a variety of linker molecules, or vice versa, in order to generate a library of related STAMPs. Previously, we successfully demonstrated a pilot version of this approach when constructing G10KHc (6), a STAMP with Pseudomonas-selective activity, and when designing C16G2 (7), a STAMP specific for Streptococcus mutans, the leading causative agent of human tooth decay.

In this study, synthetic targeting and antimicrobial peptide libraries were utilized as building blocks to generate a number of novel STAMPs with S. mutans-selective activity. STAMPs designed by these methods were then improved through tuning the linker and killing peptides present to yield completed lead STAMP molecules that demonstrated activity against S. mutans biofilms.



Wang resin, Rink-4-methylbenzhydrylamine (MBHA) resin, 9-fluorenylmethoxycarbonyl (Fmoc) amino acids, N-hydroxybenzotriazole hydrate (HOBT), and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were obtained from Anaspec (San Jose, CA). All other solvents and reagents were purchased from Fisher Scientific (Pittsburgh, PA) and were of high-pressure liquid chromatography (HPLC) or peptide synthesis grade. PerioGard (chlorhexidine gluconate oral rinse; Colgate-Palmolive, New York, NY) was utilized as 0.12% chlorhexidine where noted.

Bacterial growth.

S. mutans wild-type UA159 (1) and JM11 (spectinomycin resistant; constructed from UA140) (6), Streptococcus gordonii Challis (DL1), Streptococcus sobrinus ATCC 33478, Streptococcus mitis ATCC 903, and Streptococcus sanguinis NY101 strains were grown in brain heart infusion (BHI) or Todd-Hewitt (TH) medium at 37°C under anaerobic conditions (80% N2, 10% CO2, 10% H2) (6). Pseudomonas aeruginosa (PAK) (22) and Escherichia coli W3110 (25) strains were cultured in Luria-Bertani (LB) medium in an aerobic atmosphere at 37°C. Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE) were grown in BHI medium under aerobic conditions at 37°C (4).

Peptide synthesis and purification.

Peptides were synthesized using standard solid-phase (Fmoc) chemistry with an Apex 396 peptide synthesizer (Aapptec, Louisville, KY) at a 0.01 mM scale. N-terminal deblocking was conducted with 0.6 ml of 25% (vol/vol) piperidine in dimethylformamide (DMF), followed by agitation for 27 min and wash cycles with dichlormethane (DCM) (1 ml; one wash cycle) and N-methylpyrrolidone (NMP) (0.8 ml; seven wash cycles). Subsequent amino acid coupling cycles were conducted with a mixture of Fmoc-protected amino acid (5 eq), HOBT (5 eq), HBTU (5 eq), N,N-diisopropylethylamine (DIEA; 10 eq)-DMF (0.1 ml), and NMP (0.2 ml) with agitation for 45 min. The washing cycle was repeated before the next round of deprotection and coupling. After synthesis, peptides were washed in methanol and dried for 24 h. Protected peptides were cleaved with 1 ml of trifluoroacetic acid (TFA)-thioanisole-water-1,2-ethanedithiol (10 ml:0.5 ml:0.5 ml:0.25 ml) for 3 h at room temperature and the resultant peptide solution was precipitated in methyl tert-butyl ether.

Analytical and preparative HPLC was conducted as described previously (5, 11) to refine each peptide to 80 to 90% purity. Correct peptide mass values were confirmed by matrix-assisted laser desorption ionization (MALDI) (Voyager 4219 workstation; Applied Biosystems, Foster City, CA) or electrospray ionization (ESI) mass spectroscopy (Waters 3100 mass detector; Waters, Milford, MA) as described previously (11). Measurements were made in linear, positive ion mode with an α-cyano-4-hydroxycinnamic acid matrix where appropriate (data not shown). Fluorescent labels were added to the peptide N terminus as described previously (7). Briefly, a 4 molar excess of 5,6-carboxyfluorescein was added to the resin in 10-eq DIEA for 2 h after assembly of the linear sequence prior to cleavage.

Binding of targeting peptides to biofilms.

The binding of targeting peptides and STAMPs was assessed by fluorescence microscopy. S. mutans UA159 was grown overnight and diluted at 1:5,000 in fresh TH medium with 1% sucrose before 400 μl was seeded to 48-well flat-bottom plates (Costar, Lowell, MA). Biofilms were grown for 24 h, and the spent medium was replaced with buffer (10 mM NaHCO3, 20 mM HEPES, 150 mM NaCl, 1 mM MgCl2, 0.1% cetyltrimethylammonium bromide [CTAB], pH 7.4) containing 25 μM peptide. After 3 min of incubation at room temperature, the supernatants were removed and the biofilms washed twice with buffer prior to the acquisition of bright-field and green fluorescence images (Nikon E400 microscope) (green channel exposure, 350 ms). Digital images were collected and analyzed with the software supplied by the manufacturer (SPOT; Diagnostics) (6). To quantitate binding, biofilm-associated green pixels were selected from each image by the use of Gimp software ( and expressed as binding intensity units, as described previously (14).

MICs of peptides.

Peptide MICs were determined by broth microdilution (6, 20). Briefly, 2-fold serial dilutions of each peptide were prepared with 50% BHI medium-50% sterile water (for oral streptococci; all other bacteria were diluted in 1× Mueller-Hinton broth) at a volume of 100 μl per well in 96-well flat-bottom microtiter plates. The concentrations of peptides for the first test round ranged from 500 to 0.97 μg/ml. If activity was detected below 62.5 μg/ml, a second round of MIC tests with concentrations of 64 to 0.5 μg/ml was conducted in some cases, and the mode of the results from the second round was reported. In either case, the microtiter plate was inoculated with a bacterial cell suspension at a final concentration of ~1 × 105 CFU/ml and incubated at 37°C for 16 to 20 h under the appropriate conditions. After incubation, absorbance at 600 nm (A600) was measured using a microplate UV-Vis spectrophotometer (model 3550; Bio-Rad, Hercules, CA) to assess cell growth. The MIC endpoint was calculated as the lowest concentration of antibacterial agent that completely inhibited growth or that produced an at least 90% reduction in turbidity compared with that of a peptide-free control. At least 3 independent tests were conducted per peptide. For peptides insoluble in aqueous solutions, stock solutions were prepared in 50% methanol and appropriate solvent controls were utilized. Cell growth was not affected by 5% (vol/vol) methanol, as described previously (12).

Peptide killing kinetics.

To determine antimicrobial kinetics and specificity, assays similar to traditional time-kill experiments were performed, as described previously (6, 7). Briefly, overnight bacterial cultures were diluted in BHI medium to an A600 of 0.08 and peptides were added as indicated. Aliquots were then removed at various intervals and diluted at 1:50 in BHI medium and kept on ice until being plated on appropriate growth medium. After 24 h of incubation, colonies were counted and the numbers of surviving colony-forming units per milliliter determined. All assays were repeated at least three times; the average numbers of recovered colony-forming units per milliliter and standard deviations were determined. Statistical analysis was conducted utilizing an unpaired Student t test.

Activity against monoculture S. mutans biofilms.

STAMPs were tested for antibiofilm activity as described previously (6). Briefly, overnight cultures of S. mutans were diluted 1:50 in TH broth medium supplemented with 0.5% (wt/vol) sucrose and 100 μl of bacterial suspension was added to each well of a 96-well microtiter plate. After centrifugation, bacteria were then incubated under anaerobic conditions at 37°C for 4 h. Supernatants were then removed and replaced with 25 μM peptide-1× phosphate-buffered saline (PBS) for 30 s to 1 min, followed by removal, washing, and replacement with 100 μl of fresh TH broth (without sucrose). Plates were then incubated at 37°C under anaerobic conditions, and the bacterial recovery was monitored by recording A600 values after 4 h of incubation. An unpaired Student t test was utilized for statistical analysis.

Activity against multispecies biofilms.

Defined mixed-species biofilms were grown in 48-well flat-bottom plates (400 μl per well) in TH medium supplemented with 50% (vol/vol) filter-sterilized human saliva (pooled from healthy volunteers) and 1% sucrose. Biofilms were inoculated with S. mutans JM11 (grown overnight and seeded at a final concentration of 1 × 106 CFU/well) and Streptococcus oralis, S. gordonii, S. sanguinis, S. mitis, and S. salivarius (grown overnight and adjusted to 2 × 105 CFU/well each). Biofilms were incubated 24 h at 37°C under anaerobic conditions. After growth, biofilms were washed once with 1× PBS to remove loose aggregates and treated with 50 μM peptide-200 μl of 1× PBS (or with a commercial agent) for 10 min. Posttreatment, biofilms were mechanically detached and disrupted by scraping and agitation followed by resuspension in 100 μl of 1× PBS. Suspensions were serially diluted and plated on TH agar (to measure total numbers of surviving oral streptococci) and on TH agar supplemented with 800 μg/ml spectinomycin (to quantitate numbers of S. mutans JM11 colony-forming units per milliliter). The detection level of the assay was 100 CFU/ml. The antimicrobial effects of peptide against total biofilm or S. mutans populations and the ratio of surviving S. mutans bacteria to total numbers of oral streptococci were then calculated.


STAMPs consist of 3 regions: one targeting region and one antimicrobial region, connected via a flexible linker region. For this report, we conjoined examples of each to construct a pool of initial STAMP candidates. These peptides were then evaluated for anti-S. mutans activity and selectivity, their design was improved, and the activity of the resultant STAMPs against S. mutans and mixed-species biofilms was evaluated.

Selection of components and STAMP library 1 design.

As described elsewhere, we generated several novel S. mutans-specific binding peptides, including Sm8 (previously S3L1-10 [FIKDFIERF]) and Sm4 (previously S3L1-5 [WWYNWWQDW]) (7). In order to generate additional potential S. mutans targeting domains, residues differing in hydrophobicity and/or charge were replaced at defined positions with respect to these base sequences to yield a series of related peptides that were then evaluated for binding to S. mutans biofilms (a list is presented in Table Table1).1). As shown in Fig. Fig.1,1, several of the variants were found to retain biofilm binding, whereas Bc1 ([AAKHAAHRA]), a control peptide not related to Sm4 or Sm8, failed to bind to S. mutans. Therefore, peptides Sm1, Sm2, Sm3, Sm5, Sm6, and Sm7, as well as peptide Sm4, were regarded in the present study as the pool of S. mutans targeting vectors for library 1 STAMP construction. For the antimicrobial component, we selected PL-135, a short peptide based on an AMP isolated from tunicates (24), for the initial round of design. We hypothesized that linker regions and attachment orientations would exert an influence on STAMP activity. Therefore, we conjugated each potential targeting peptide to the N or C terminus of PL-135 through six different linkers (GGG [designated L1], SAT [L3], ASASA [L5], PYP [L7], PSGSP [L8], and PSPSP [L9]), as shown in Table Table1,1, leading to the synthesis of 84 STAMPs.

FIG. 1.
Binding of targeting peptides to S. mutans biofilms. Fluorescently labeled peptides were evaluated for binding to S. mutans biofilms. After incubation with 25 μM peptide, biofilms were washed repeatedly prior to acquisition of bright-field (right ...
STAMP constituent regions utilized in STAMP libraries 1 and 2

Activity of STAMP library 1.

To roughly gauge STAMP antimicrobial activity and S. mutans selectivity, MIC assays were conducted with S. mutans and a panel of bacteria, including two oral Streptococcus species, S. sanguinis and S. sobrinus (Table (Table2).2). Of the 84 molecules, STAMPs containing Sm6 conjoined to the C terminus of PL-135 [PL(L1)Sm6, PL(L3)Sma6, PL(L5)Sm6, PL(L7)Sm6, PL(L8)Sm6, and PL(L9)Sm6] or Sm7 conjoined to the N terminus of PL-135 [Sm7(L1)PL] were found to be active against S. mutans at concentrations lower than 100 μg/ml. These peptides were more active (two to four 2-fold-dilution steps) against S. mutans than against the other oral streptococci or the nonoral organisms tested. In contrast, native PL-135 had similar MICs for all strains examined (Table (Table22).

MICs of activea library 1 and library 2 STAMPs

Further potential of PL-135-based STAMPs.

Antiseptic oral rinses, such as chlorhexidine or Listerine (Johnson and Johnson, New Brunswick, NJ), are rapid-acting nonselective bactericidal agents that can inactivate bacteria within seconds of contact (3). In order for STAMPs to be useful oral rinse ingredients, the antimicrobial kinetics must approach this scale. Therefore, the killing kinetics of the lead library 1 STAMPs from Table Table22 were evaluated (data not shown). The results indicate that these PL-135-containing STAMPs, although selective for S. mutans when measured by MIC, are not rapid killers of this bacterium in vitro, requiring several hours of exposure for observable antimicrobial activity. Therefore, we sought to improve our STAMP pool by substituting alternative AMP domains for S. mutans STAMP construction.

Library 2: tuning the design of Sm6-containing STAMPs.

We conjugated Sm6 with RWRWRWF(2C-4), FKKFWKWFRRF(B-33), IKQLLHFFQRF(B-38), RWRRLLKKLHHLLH(α-11), and LQLLKQLLKLLKQF(α-7) (attached at the C or N terminus), five AMPs selected from our previous studies (12), to construct library 2. The linkers selected to make a total of 40 STAMPs were L1, SGG (L6), L3, and LC (8-amino caprylic acid) (Table (Table11).

As shown in Table Table2,2, over half the library 2 STAMPs (n = 24) had MICs under 100 μg/ml for S. mutans (unlike library 1). Additionally, MICs were improved 2- to 8-fold compared with active PL-135-containing constructs. Within library 2, little difference in activity was observed between constructs where the targeting peptide was attached to the N or C terminus of the AMP region, and little MIC change between linkers employed was noted. It was also apparent that, in nearly all cases, these STAMPs were more active against S. mutans than against the other oral and nonoral bacteria tested. Peptide Sm6(L1)B33 demonstrated the lowest MIC mode at 4 μg/ml, which was an improvement over the MIC for the killing peptide alone (12).

Due to increased potency of library 2 versus library 1 constructs, we investigated the function of the Sm6 targeting region within each set of STAMPs by examining binding to S. mutans biofilms. As shown in Fig. Fig.22 and and3,3, STAMPs from library 1 were found to have significantly lower binding intensities than library 2 constructs (Student's t test; P < 0.01). In addition, there was an obvious increase in library 2 STAMP binding to S. mutans biofilms versus parent AMP results [Fig. [Fig.22 and and3;3; compare B-33 or 2C-4 alone to Sm6(L1)2C, Sm6(L3)2C, or Sm6(L1)B33], suggesting that the targeting peptide was functioning as hypothesized. Interestingly, the biofilm labeling intensities for library 2 STAMPs where Sm6 was attached at the N or C terminus of the AMP region were similar [the results for Sm6(L3)α11 and α11(L3)Sm6 are shown as examples].

FIG. 2.
Binding of STAMPs and AMPs to S. mutans biofilms. S. mutans biofilms were grown for 24 h and exposed to 25 μM STAMP (or untargeted AMP B-33 or 2C-4) for 3 min. Postincubation, biofilms were washed repeatedly and bright-field (right panels) and ...
FIG. 3.
Quantitative analysis of peptide binding to S. mutans biofilms. As described for Fig. Fig.11 and and2,2, the binding of 25 μM targeting peptide, AMP, or STAMP to mature S. mutans biofilms was analyzed by fluorescence microscopy ...

Taken together, these data suggest that library 2 STAMPs can effectively inhibit the growth of S. mutans at generally improved potencies compared to the PL-135-containing STAMPs in library 1 and that Sm6-dependent biofilm binding is retained in potent STAMP constructs.

STAMP killing kinetics against oral bacteria.

Since the MIC assay measures antimicrobial activity after overnight incubation, large differences in killing rates between STAMPs and parental AMPs may be obscured in this assay, especially when the target organism is susceptible to the AMP (7, 11). To further assess any significant selectivity and short-term antimicrobial activity of the library 2 STAMPs, time-kill assays were performed using a variety of oral bacteria. Against the targeted bacterium S. mutans (examples shown in Fig. Fig.4D),4D), the STAMPs acted significantly faster than the killing peptide alone within 5 min of treatment [P < 0.001, comparing B-33 alone to Sm6(L1)B33 at 1 min or 2C-4 versus either 2C-4-containing STAMP at 5 min]. In contrast, other oral streptococci, such as S. mitis and S. gordonii, were less affected by STAMP treatments (Fig. 4A to C). Peptide Sm6(L1)B33 exhibited the fastest killing kinetics and best selectivity: killing was observed even when cells were treated for as little as 30s, a timescale more appropriate for oral cavity therapeutic applications. As expected from their wide spectra of activities (12), parental AMPs 2C-4 and B-33 had similar levels of activity against the strains examined.

FIG. 4.
Killing kinetics of selected peptides against oral streptococci. All tested bacteria, including S. mitis (Smit) (A), S. gordonii (Sgor) (B), S. sanguinis (Ssang) (C), and S. mutans UA159 (Smut) (D), were treated with peptide solutions at 25 μg/ml ...

Activity against monoculture S. mutans biofilms.

Although rapid killing of S. mutans planktonic monocultures was apparent from the data shown in Fig. Fig.4,4, it remained unclear whether these STAMPs would make suitable antimicrobial agents in the oral cavity, where dental plaque biofilms predominate (21, 23). To investigate, S. mutans biofilms were treated with STAMP, Listerine, or 0.12% chlorhexidine and the postantibiotic effect was observed after 4 h. As shown in Fig. Fig.5,5, STAMPs Sm6(L1)2C, Sm6(L3)2C, and Sm6(L1)B33 were found to significantly (P < 0.001) inhibit the viability of biofilms when cells were treated with the peptide for 1 min at 25 μg/ml, compared to the viability seen with mock-treated biofilms or biofilms treated with untargeted AMP. Similar antimicrobial effects were observed for Listerine and chlorhexidine. These results suggest that STAMP treatment results in a level of S. mutans biofilm killing similar to that observed with established wide-spectrum oral antiseptics.

FIG. 5.
Inhibitory activity of STAMPs against monoculture biofilms. S. mutans biofilms were grown and exposed to 25 μg/ml of STAMP, unmodified parental AMP, or oral antiseptic (for 1 min), washed, and replenished with fresh medium. Levels of bacterial ...

Activity against mixed-species biofilms.

To fully evaluate selectivity and activity, mature biofilms consisting of S. mutans and other oral streptococci were grown in saliva and treated with a STAMP, a parental AMP, or an oral antiseptic, and the surviving numbers of colony-forming units per milliliter were quantitated. As shown in Fig. Fig.6A,6A, compared with untreated biofilms, >95% of both S. mutans and non-S. mutans oral streptococci (as measured in numbers of colony-forming units per milliliter) were eliminated after chlorhexidine or Listerine treatment, which is consistent with the nonspecific activity of these agents. In contrast, Sm6(L1)B33 treatment resulted in a strong decrease in recoverable S. mutans numbers, whereas the population of non-S. mutans oral streptococci was less affected. This resulted in a ratio of surviving S. mutans to oral streptococci of <0.1 for these samples (Fig. (Fig.6B).6B). The remaining STAMPs tested, as well as the parental B-33 and 2C-4 AMPs, were largely ineffective, though B-33, Sm6(L1)2C, and Sm6(L3)2C showed a modest degree of antimicrobial selectivity toward S. mutans. Overall, these results suggest that Sm6(L1)B33 retains robust activity and selectivity for S. mutans in a mixed-species biofilm system.

FIG. 6.
Activity and selectivity of STAMPs against multispecies biofilms. Defined mixed-species biofilms of S. mutans and other oral streptococci were grown in 50% saliva prior to treatment with STAMP, parental AMP, or a commercial product. (A) Antimicrobial ...


In this report, we present a novel strategy for the design and synthesis of STAMPs with activity against the oral pathogen S. mutans. Successful design was achieved through a tunable, building-block approach that utilized various combinations of antimicrobial, targeting, and linker regions. Our results demonstrate that less-efficacious STAMPs can be improved when alternative killing regions are substituted in the design. This process resulted in Sm6(L1)B33, a STAMP that displayed killing kinetics consistent with oral therapeutic applications and selectivity for S. mutans in multispecies biofilms.

The data presented suggest that the activity of the PL-135 AMP may be inhibited by conjugation to other peptide subunits, as unmodified PL-135 displayed MIC activity against S. mutans that was 2- to 8-fold better than that of progeny STAMPs, as shown in Table Table2.2. Furthermore, library 1 STAMPs exhibited significantly reduced biofilm binding compared to library 2 conjugates with identical targeting regions, suggesting PL-135 interference in Sm6 activity as well. The unusually small size of PL-135 may impose a severe restriction on amino acid additions, especially when the mode of antimicrobial action depends on sequence-dependent self-association on the cell membrane or on binding to a discrete intracellular bacterial target (2). It remains unclear why PL-135 should inhibit Sm6 targeting peptide function.

Our results suggest that the optimal arrangement of STAMP domains is likely AMP specific and depends on which of the domains least affects, or even enhances, the antimicrobial mechanism. For example, the Pseudomonas-specific STAMPs G10KHc and G10KHn (oriented as target domain-killing domain and killing domain-target domain, respectively) both bind specifically to the target bacterium surface, but only G10KHc shows significant membrane disruption activity (5, 7). Further biochemical studies of pilot STAMP libraries of greater diversity are being conducted to fully evaluate whether correct pairings can be more accurately predicted.

Interestingly, Sm6 and Sm7 containing library 1 STAMPs were active against S. mutans, whereas the constructs with any one of the other targeting peptides listed in Table Table11 were not. Targeting peptides Sm1 through Sm5 are strongly hydrophobic compared with Sm6 and Sm7 (8), and it may be possible that this characteristic limits the dissociation of these molecules from the hydrophobic components of the S. mutans cell wall, resulting in their inhibitory affect on AMPs when conjugated, in similarity to the results seen with some strong lipopolysaccharide (LPS)-binding AMPs (19). However, the systematic design strategy employed here allowed us to generate a diverse array of STAMPs, including useful compounds such as Sm6(L1)B33, despite these stumbling blocks.

It remains to be seen whether the selectivity observed with the STAMPs described in this report can be maintained in the oral cavity during treatment. Typically, oral-care antimicrobials are applied at high doses, suggesting that any selectivity “window” would be overwhelmed by nonspecific STAMP activity at higher concentrations. However, there are up to a total of 1 × 108-9 CFU/ml of bacteria in the mouth, of which as many as 1 × 107/ml can be S. mutans (9, 10). These bacterial burden levels are 10 to 100 times higher than those employed in the assays reported here, which suggests that typical oral therapeutic concentrations are necessary for activity and selectivity. Additionally, the typical 30 s to 2 min of treatment duration for oral rinse formulations may limit STAMP antimicrobial activity to targeted organisms, as seen in Fig. Fig.44.

In conclusion, this report details the rational design of S. mutans-selective STAMPs with enhanced antimicrobial killing kinetics and selectivity compared to untargeted AMPs. The S. mutans-selective STAMPs were constructed using a tunable, combinatorial approach that generated a diverse number of STAMP sequences for antimicrobial evaluation and improvement, a process that may serve as an example for the systematic development of novel selective antimicrobial agents. We propose that these STAMPs could be useful in the design of therapeutics against oral or other mucosal pathogens, where the high diversity of “probiotic” beneficial microflora limits the effectiveness of broad-spectrum antimicrobial agents.


We are grateful to R. I. Lehrer (University of California, Los Angeles) for the donation of PL-135 and to A. Kolesnikova for technical assistance.

This work was supported by grants from the NIH (MD01831) to M.H.A. and W.S. and from C3 Jian Inc.


[down-pointing small open triangle]Published ahead of print on 8 March 2010.


1. Ajdić, D., W. M. McShan, R. E. McLaughlin, G. Savic, J. Chang, M. B. Carson, C. Primeaux, R. Tian, S. Kenton, H. Jia, S. Lin, Y. Qian, S. Li, H. Zhu, F. Najar, H. Lai, J. White, B. A. Roe, and J. J. Ferretti. 2002. Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc. Natl. Acad. Sci. U. S. A. 99:14434-14439. [PubMed]
2. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250. [PubMed]
3. Charles, C. H., P. C. Pan, L. Sturdivant, and J. W. Vincent. 2000. In vivo antimicrobial activity of an essential oil-containing mouthrinse on interproximal plaque bacteria. J. Clin. Dent. 11:94-97. [PubMed]
4. Chen, L., X. Cheng, W. Shi, Q. Lu, V. L. Go, D. Heber, and L. Ma. 2005. Inhibition of growth of Streptococcus mutans, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant enterococci by kurarinone, a bioactive flavonoid isolated from Sophora flavescens. J. Clin. Microbiol. 43:3574-3575. [PMC free article] [PubMed]
5. Eckert, R., K. M. Brady, E. P. Greenberg, F. Qi, D. K. Yarbrough, J. He, I. McHardy, M. H. Anderson, and W. Shi. 2006. Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob. Agents Chemother. 50:3833-3838. [PMC free article] [PubMed]
6. Eckert, R., J. He, D. K. Yarbrough, F. Qi, M. H. Anderson, and W. Shi. 2006. Targeted killing of Streptococcus mutans by a pheromone-guided “smart” antimicrobial peptide. Antimicrob. Agents Chemother. 50:3651-3657. [PMC free article] [PubMed]
7. Eckert, R., F. Qi, D. K. Yarbrough, J. He, M. H. Anderson, and W. Shi. 2006. Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp. Antimicrob. Agents Chemother. 50:1480-1488. [PMC free article] [PubMed]
8. Fauchere, J. L., and V. Pliska. 1983. Hydrophobic parameters—pi of amino-acid side-chains from the partitioning of N-acetyl-amino-acid amides. Eur. J. Med. Chem. 18:369-375.
9. Fung, A., C. Y. Yang, S. Freire, C. Montemagno, B. Brough, C. M. Ho, F. Gu, and W. Shi. 2005. Fluorescent detection of oral pathogens by a solid-phase immunoassay on PDMS. Conf. Proc. IEEE Eng. Med. Biol. Soc. 3:2630-2633. [PubMed]
10. Gu, F., R. Lux, M. H. Anderson, M. A. del Aguila, L. Wolinsky, W. R. Hume, and W. Shi. 2002. Analyses of Streptococcus mutans in saliva with species-specific monoclonal antibodies. Hybrid Hybridomics 21:225-232. [PubMed]
11. He, J., M. H. Anderson, W. Shi, and R. Eckert. 2009. Design and activity of a ‘dual-targeted’ antimicrobial peptide. Int. J. Antimicrob. Agents 33:532-537. [PMC free article] [PubMed]
12. He, J., R. Eckert, T. Pharm, M. D. Simanian, C. Hu, D. K. Yarbrough, F. Qi, M. H. Anderson, and W. Shi. 2007. Novel synthetic antimicrobial peptides against Streptococcus mutans. Antimicrob. Agents Chemother. 51:1351-1358. [PMC free article] [PubMed]
13. Isturiz, R. 2008. Global resistance trends and the potential impact on empirical therapy. Int. J. Antimicrob. Agents 32(Suppl. 4):S201-S206. [PubMed]
14. Li, L., J. He, R. Eckert, D. Yarbrough, R. Lux, M. Anderson, and W. Shi. 2010. Design and characterization of an acid-activated antimicrobial peptide. Chem. Biol. Drug Des. 75:127-132. [PMC free article] [PubMed]
15. Liévin-Le Moal, V., and A. L. Servin. 2006. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin. Microbiol. Rev. 19:315-337. [PMC free article] [PubMed]
16. Lopez, A. D., C. D. Mathers, M. Ezzati, D. T. Jamison, and C. J. Murray. 2006. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747-1757. [PubMed]
17. Marsh, P. D. 2003. Are dental diseases examples of ecological catastrophes? Microbiology 149:279-294. [PubMed]
18. Mokdad, A. H., J. S. Marks, D. F. Stroup, and J. L. Gerberding. 2004. Actual causes of death in the United States, 2000. JAMA 291:1238-1245. [PubMed]
19. Patrzykat, A., C. L. Friedrich, L. Zhang, V. Mendoza, and R. E. Hancock. 2002. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob. Agents Chemother. 46:605-614. [PMC free article] [PubMed]
20. Qi, F., J. Kreth, C. M. Levesque, O. Kay, R. W. Mair, W. Shi, D. G. Cvitkovitch, and S. D. Goodman. 2005. Peptide pheromone induced cell death of Streptococcus mutans. FEMS Microbiol. Lett. 251:321-326. [PubMed]
21. Ruby, J., and M. Goldner. 2007. Nature of symbiosis in oral disease. J. Dent. Res. 86:8-11. [PubMed]
22. Strom, M. S., and S. Lory. 1986. Cloning and expression of the pilin gene of Pseudomonas aeruginosa PAK in Escherichia coli. J. Bacteriol. 165:367-372. [PMC free article] [PubMed]
23. ten Cate, J. M. 2006. Biofilms, a new approach to the microbiology of dental plaque. Odontology 94:1-9. [PubMed]
24. Tincu, J. A., L. P. Menzel, R. Azimov, J. Sands, T. Hong, A. J. Waring, S. W. Taylor, and R. I. Lehrer. 2003. Plicatamide, an antimicrobial octapeptide from Styela plicata hemocytes. J. Biol. Chem. 278:13546-13553. [PubMed]
25. Zinder, N. D., and V. Lederberg. 1952. Genetic exchange in Salmonella. J. Bacteriol. 64:679-699. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)